DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Eplerenone and Extracellular Adenosine Formation

Information source: Radboud University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Pharmacodynamics

Intervention: Eplerenone (Drug); Placebo (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Radboud University

Official(s) and/or principal investigator(s):
Niels Riksen, Dr., Principal Investigator, Affiliation: Radboud University Medical Centre Nijmegen
Gerard Rongen, Prof., Study Chair, Affiliation: Radboud University Medical Centre Nijmegen

Summary

Various studies have reported cardioprotective effects of mineralocorticoid receptor (MR) antagonists in the setting of an acute myocardial infarction. In a recent animal study, the protective effect of MR antagonists on infarct size was completely abolished in CD73 knock-out and adenosine A2b receptor knock-out mice, and by co-administration of adenosine receptor antagonists in rats. These findings suggest that extracellular formation of adenosine is crucial for this protective effect and that MR antagonists stimulate extracellular adenosine formation by the enzyme CD73. To investigate whether eplerenone promotes adenosine receptor stimulation by activating CD73, the investigators will measure forearm blood flow in response to various dosages of dipyridamole with the use of plethysmography. Dipyridamole increases the extracellular endogenous adenosine concentration by inhibition of the ENT transporter and induces local vasodilation. Therefore, the vasodilator effect of dipyridamole accurately reflects extracellular adenosine formation by the CD73 enzyme.

Clinical Details

Official title: Effects of the Selective Mineralocorticoid Receptor Antagonist Eplerenone on Extracellular Adenosine Formation in Humans in Vivo

Study design: Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science

Primary outcome: forearm blood flow response

Secondary outcome:

forearm blood flow

forearm blood flow

Eligibility

Minimum age: 18 Years. Maximum age: 40 Years. Gender(s): Male.

Criteria:

Inclusion Criteria:

- Male sex

- Age 18-40 years

- Healthy

- Written informed consent

Exclusion Criteria:

- Smoking

- Hypertension (Blood pressure >140 mmHg and/or >90 mmHg - SBP/DBP-)

- Hypotension (Blood pressure <100 mmHg and/or <60 mmHg -SBP/DBP-)

- Diabetes Mellitus (fasting glucose > 6. 9 mmol/L or random > 11. 0 mmol/L in venous

plasma)

- History of any cardiovascular disease

- Angina pectoris

- History of chronic obstructive pulmonary disease (COPD) or asthma

- Alcohol and/or drug abuse

- Concomitant use of medication

- Renal dysfunction (MDRD < 60 ml/min/1. 73 m2)

- Liver enzyme abnormalities (ALAT > twice upper limit of normality)

- Serum potassium ≥ 4. 8 mmol/L

- Fasting total cholesterol > 6. 0 mmol/L

- Second/third degree AV-block on electrocardiography

Locations and Contacts

Radboud University Medical Centre, Nijmegen, Gelderland 6525EZ, Netherlands
Additional Information

Starting date: April 2013
Last updated: January 8, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017